Please login to the form below

Not currently logged in
Email:
Password:

Astellas and Regeneron extend deal

Astellas has agreed to pay Regeneron $295m to extend its non-exclusive licence of the company's VelocImmune drug-discovery technology to 2023

Astellas has agreed to pay Regeneron $295m to extend its non-exclusive licence of the company's VelocImmune drug-discovery technology through the year 2023.

The licence allows Astellas to make use of VelocImmune technology in its internal research programs to discover fully human monoclonal antibody product candidates. The deal calls for a $165m upfront payment, with another $130m due in June 2018. Astellas will also pay a mid-single-digit royalty on product sales of any marketed therapies developed using the technology.

The companies forged their original six-year licensing deal in early 2007. That deal, which is overturned by the new agreement, called for Astellas to make licensing payments of $20m per year during 2007 to 2010.

Although no Astellas products making use of the technology have yet been approved, about 20 monoclonal antibody projects using VelocImmune are ongoing at the company. Astellas said that the extension of the deal is part of its recently announced mid-term management plan toward the financial year 2014, which calls for the company to put "the highest strategic priority on the development of antibody drugs."

The VelocImmune technology generates fully human monoclonal antibodies (hMAbs) to address clinically relevant targets.

28th July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides market research, insights, and scientific and medical communication services to the pharmaceutical industry across the...

Latest intelligence

Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...
Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...

Infographics